RCS - Ondine Biomedical - Growing Use of Steriwave Across Surgery Types

Ondine BiomedicalAnnouncement

14/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nRSN8266Qa&default-theme=true

RNS Number : 8266Q  Ondine Biomedical Inc.  14 July 2025

14 July 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Growing Use of Steriwave Across Surgery Types

Ondine Biomedical Inc. (AIM: OBI) reports increasing clinical adoption of its
light-activated antimicrobial therapy, Steriwave(®), across a broad range of
surgical specialities in hospitals throughout the UK and Canada to reduce
surgical site infections (SSIs).

Hospitals are now routinely implementing Steriwave nasal decolonisation prior
to major surgeries - including cardiac, orthopaedic, neurosurgical, ENT,
spinal, and cosmetic procedures - as awareness grows of its effectiveness in
reducing SSIs.

SSIs remain a significant concern in surgical care, contributing to
approximately 3% mortality, 1  (#_edn1) extended hospital stays averaging
nearly 10 additional days. 2  (#_edn2) A comprehensive study in Alberta,
Canada, found that complex SSIs following hip and knee replacements can cost
hospitals up to CA$95,000 per case and pose serious health risks for
patients. 3  (#_edn3)

The patient's nasal passages are a significant source of post-surgical
infections, with studies indicating that up to 69% of SSIs originate from
pathogens that can colonise the nose. 4  (#_edn4)  5  (#_edn5) - 6  (#_edn6)
Leading health authorities, including the CDC, WHO, and SHEA, strongly
recommend pre-operative nasal decolonisation as an effective strategy to lower
the risk of infection. Steriwave offers a cutting-edge, light-activated
antimicrobial therapy designed to eliminate these nasal pathogens, thereby
enhancing patient safety and surgical outcomes.

Carolyn Cross, CEO of Ondine, commented:

"It's encouraging to see Steriwave gaining recognition across such a wide
range of surgical specialties. In contrast to mupirocin - the current standard
for nasal decolonisation despite its limited bacterial spectrum and rising
resistance - Steriwave offers a fast-acting, resistance-free alternative that
is effective across nasal pathogens, including bacteria, viruses and fungi. In
some hospitals, mupirocin resistance exceeds 70%, underscoring the urgent need
for more versatile and reliable infection prevention tools like Steriwave."

Steriwave is a non-invasive, painless nasal treatment that uses a proprietary
photosensitive agent activated by red light to destroy harmful bacteria,
viruses, and fungi. The procedure takes five minutes, is effective
immediately, and allows the normal nasal microbiome to recover quickly,
without fostering antimicrobial resistance.

Steriwave is actively utilized in hospitals across Canada, including more than
half of the country's ten largest hospitals, as well as several prominent NHS
Trusts in the UK. In the United States, the technology is currently undergoing
a Phase 3 clinical trial in collaboration with HCA Healthcare, the nation's
largest private healthcare group. This study aims to secure FDA marketing
approval, further expanding Steriwave's reach and impact.

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Advisor)
 James Steel, Dr. Chris Golden                               +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

(#_ednref1)  1  Umscheid CA, et al. Estimating the proportion of
healthcare-associated infections that are reasonably preventable and the
related mortality and costs. Infection Control & Hospital Epidemiology,
2011;32(2):101-114. (link (https://doi.org/10.1086/657912) )

(#_ednref2)  2  Anderson DJ, et al. Strategies to Prevent Surgical Site
Infections in Acute Care Hospitals: 2014 Update. Infect. Control. Hosp.
Epidemiol. 2014;35:605-627. (link
(https://pmc.ncbi.nlm.nih.gov/articles/PMC4267723/) )

(#_ednref3)  3  Rennert-May ED, Conly J, Smith S, et al. The cost of managing
complex surgical site infections following primary hip and knee arthroplasty:
A population-based cohort study in Alberta, Canada. Infect Control Hosp
Epidemiol. 2018;39(10):1183-1188. (link
(https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/abs/cost-of-managing-complex-surgical-site-infections-following-primary-hip-and-knee-arthroplasty-a-populationbased-cohort-study-in-alberta-canada/D1039C9F16AC6FE965C960D6C2494201)
)

(#_ednref4)  4  CDC. HAI Pathogens and Antimicrob Resist Report, 2018-2021.
(link (https://www.cdc.gov/nhsn/hai-report/index.html) )

(#_ednref5)  5  Nature. 2012;486:207-214. (link
(https://www.nature.com/articles/nature11234) )

(#_ednref6)  6  Biomedicines. 2022 Dec 26;11(1):54. (link
(https://www.mdpi.com/2227-9059/11/1/54/review_report) )

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKNBBKBKDBOD